Aquestive Therapeutics, Inc. AQST Liability related to the sale of future revenue, net
Liability related to the sale of future revenue, net at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, net?
- Aquestive Therapeutics, Inc. (AQST) reported liability related to the sale of future revenue, net of $62.08M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, net changed year-over-year?
- Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, net decreased by 1.1% year-over-year, from $62.78M to $62.08M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, net?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, net has grown at a 5.5% compound annual growth rate (CAGR), from $47.52M to $62.02M.
- What does liability related to the sale of future revenue, net mean?
- This represents the long-term liability associated with the sale of future revenue streams, where the transaction is accounted for as a financing arrangement. It reflects the total remaining obligation to transfer future cash flows to investors or counterparties beyond the current year. This metric is critical for understanding the long-term impact of non-dilutive financing on future revenue recognition.